Abstract
Purpose
The dose limiting toxicity of oxaliplatin (l-HOP) is neurotoxicity, which is characterized by an acute neuropathy and a clinically distinct chronic neuropathy. This randomized study evaluated if prolonged l-HOP infusion over the conventional l-HOP schedule was useful in reducing acute and possibly chronic l-HOP induced neurotoxicity in colon and gastric cancer patients receiving l-HOP-based regimen as adjuvant chemotherapy.
Methods
Sixty-four patients were randomly assigned to group A (26 colon and 6 gastric cancer) and to group B (23 colon and 9 gastric cancer). Chemotherapy in both groups consisted of l-HOP 85 mg/m2 i.v. only on day 1, with leucovorin 100 mg/m2 i.v. as a 2-h infusion followed by bolus 5-fluorouracil (5-FU) 400 mg/m2/day and a 22-h infusion of 5-FU 600 mg/m2/day, repeated for two consecutive days every 2 weeks for a maximum of 12 cycles. Patients in group A received l-HOP as a continuous 6-h i.v. infusion, and patients in group B received l-HOP as the conventional 2-h i.v. infusion.
Results
The percentage of patients presenting with grade ≥2 neurotoxicity was statistically lower in group A than in group B (28.1% vs. 59.3%: P = 0.02). There was a statistically lower percentage of cycles with grade ≥2 neurotoxicity in group A (6.1%) than in group B (18.5%) (P < 0.001).
Conclusions
This study suggests that l-HOP as a continuous 6-h infusion is useful in preventing and reducing acute l-HOP induced neurotoxicity in patients with colon and gastric cancer receiving FOLFOX-4 regimen as adjuvant treatment.
Similar content being viewed by others
References
De Gramont A, Figer A, Seymour M, et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947
Andrè T, Boni C, Mounedji-Boudiaf L, Navarro M, et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351
Louvet C, Andre T, Tigaud JM, et al (2004) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543–4548
Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658–663
Leong T (2005) Chemotherapy and radiotherapy in the management of gastric cancer. Curr Opin Gastroenterol 21:633–635
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774
Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 4:5–13
Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29(suppl 15):11–20
Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053–1071
Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13–22
Giacchetti S, Perpoint B, Zigani R, et al (2000) Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147
Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(suppl 15):21–33
Maindrault-Goebel F, de Gramont A, Louvet C, et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37:1000–1005
Goldstein D, Mitchell P, Michael M, et al (2005) Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 92:832–837
Kweekel DM, Gelderblom H, Guchelaar H-J (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90–105
Moxley RT III (2000) Channellopathies. Curr Treat Options Neurol 2:31–47
Bruguerolle B (1998) Chronopharmacokinetics: current status. Clin Pharmacokinet 35:83–94
Levi F, Zidani R, Misset JL, et al (1997) Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681–686
Levi F, Misset JL, Brienza S, et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893–900
Gamelin L, Boisdron-Celle, Delva R, et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061
Cascinu S, Catalano V, Cordella L, et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomised, double-blind, pacebo-controlled trial. J Clin Oncol 20:3478–3483
Wong GY, Michalak JC, Sloan JA, et al (2005) A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a north central cancer treatment group study. J Clin Oncol 23(Suppl 16):Abstract 8001
Mitchell PL, Goldstein D, Michael M, et al (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6:146–151
Petrioli R, Sabatino M, Fiaschi AI, et al (2004) UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 90:306–309
Tournigand C, Cervantes A, Figer A, et al (2006) OPTIMOX1: a randomized study of FOLFOX 4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer- a GERCOR study. J Clin Oncol 24:394–400
Maindrault-Goebel F, Lledo G, Chibaudel B, et al (2006) OPTIMOX2, a large randomised phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study ASCO 24:3504
Petrioli R, Paolelli L, Marsili S, et al (2006) FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology
Acknowledgments
We thank Dr. Stefania Rossi for statistical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Petrioli, R., Pascucci, A., Francini, E. et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 61, 105–111 (2008). https://doi.org/10.1007/s00280-007-0454-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0454-3